



Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Registered Office:

3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6,
Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills,
Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000, E:info@viyash.com

E: investorrelations@sequent.in

Website: www.sequent.in

CIN: L99999TS1985PLC196357

January 22, 2026

To,

BSE Limited

Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East),
Mumbai – 400 051

Scrip code: 512529

Symbol: SEQUENT

Subject: Press Release – Viyash Scientific announces partnership with Boehringer Ingelheim to expand companion animal portfolio in India

Dear Sir/ Madam,

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Press Release on the captioned subject which is self-explanatory.

The above details are also available on the website of the Company in the Investors Section at: www.sequent.in

You are requested to take the same on record.

Yours faithfully,

For Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Yoshita Vora

Company Secretary & Compliance Officer

Encl: A/a



Viyash Scientific announces partnership with Boehringer Ingelheim to expand companion animal portfolio in India

Alivira Animal Health Limited (***a wholly owned subsidiary of Viyash Scientific Limited***) has entered into a partnership agreement with Boehringer Ingelheim India Private Limited for the distribution and promotion of their companion animal products portfolio in India. This partnership is designed to capture the growing opportunities in India's pet healthcare market, driven by increased pet ownership, rising awareness of preventive care and growing emphasis on animal well-being across the country.

Speaking on the partnership, **Dr. Haribabu Bodepudi**, MD & Group CEO - Viyash Scientific Limited said, "This represents an important milestone in Viyash Scientific's journey to become a key player in the companion animal segment. India offers tremendous opportunities for innovative medicines which cater to the medical needs of our pets. Driving access to high quality solutions for our pets in urban and rural India is at the heart of this partnership. Alivira's extensive geographical reach and on-ground capabilities combined with Boehringer Ingelheim's differentiated companion animal product portfolio strengthens our ability to serve veterinarians and pet parents across India effectively."

Dr Vinod Gopal, Country Head, Animal Health, Boehringer Ingelheim India said, "This partnership aligns with our long-term growth strategy for the animal health business in India and enables us to serve our customers with greater clarity, consistency, and care. It positions us to scale efficiently while remaining focused on strategic leadership. Alivira Animal Health Limited will expand our sales capability across urban and rural India in the companion animal business, further enhancing market reach, access and driving execution excellence."

He further adds, "Our portfolio continues to be built on high-quality products, supported by a robust and advancing pipeline, ensuring sustainable growth, strong governance, and consistent delivery for our customers. Together with Alivira Animal Health Limited, we can improve access, and responsiveness while preserving a clear strategy and brand experience to support future growth of our companion animal business."

About Alivira Animal Health Limited

Alivira Animal Health Limited is a wholly owned subsidiary of Viyash Scientific Limited (formerly known as Sequent Scientific Limited). Headquartered in India, the Group is among the top 25 Animal Health companies in the world. With over 3000 talented employees, Viyash Scientific Limited is an integrated pharmaceutical company having a rich portfolio of formulations and APIs for human and veterinary use, serving customers in over 100 countries. Viyash and its subsidiaries have manufacturing, R&D and distribution operations across India, Spain, Brazil, Turkey and USA, with approvals from international regulatory bodies, including USFDA, EUGMP, WHO, TGA, etc.

Pursuant to approvals from the Registrar of Companies, SeQuent Scientific Limited has been officially renamed as Viyash Scientific Limited with effect from January 8, 2026, marking the completion of the merger between Sequent Scientific Limited and Viyash Life Sciences Private Limited.

About Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow.

Established in 2003, Boehringer Ingelheim India manages operations in India and neighboring markets, offering innovative products in Human Pharma and Animal Health, with key therapy areas including diabetes, cardiovascular, and respiratory conditions. Learn more at <https://www.boehringer-ingelheim.com/in>